DeepMed Research

UNIVERSITY OF MIAMI

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1925-01-01

Employees: 10K

Market Cap: -

Website: https://continue.miami.edu/packagedetail.aspx

Clinical Trials

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Phase 2

Withdrawn

Conditions: Gestational Trophoblastic Neoplasia

Interventions: Drug: Dostarlimab

First Posted Date: 2022-06-06

Last Posted Date: 2023-02-28

Lead Sponsor: University of Miami

Registration Number: NCT05405192

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Feeding Regulation in SCI

Not Applicable

Completed

Conditions: Spinal Cord Injuries

Interventions: Other: Test Meals

First Posted Date: 2022-06-06

Last Posted Date: 2024-02-14

Lead Sponsor: University of Miami

Target Recruit Count: 37

Registration Number: NCT05406739

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Natural Helpers and PCIT

Not Applicable

Recruiting

Conditions: Parenting
Child Behavior

Interventions: Behavioral: Standard Parent-Child Interaction Therapy (PCIT)
Behavioral: Natural Helpers (NH)

First Posted Date: 2022-06-01

Last Posted Date: 2024-12-12

Lead Sponsor: University of Miami

Target Recruit Count: 300

Registration Number: NCT05400434

Locations: 🇺🇸
ConnectFamilias, Miami, Florida, United States
🇺🇸
Mailman Center for Child Development, Miami, Florida, United States

Comprehensive Behavioral Intervention for Tics

Not Applicable

Recruiting

Conditions: Tic Disorders

Interventions: Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT)

First Posted Date: 2022-05-11

Last Posted Date: 2025-01-15

Lead Sponsor: University of Miami

Target Recruit Count: 200

Registration Number: NCT05370391

Locations: 🇺🇸
University of Miami, Coral Gables, Florida, United States

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Phase 2

Recruiting

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Sunitinib
Drug: Regorafenib

First Posted Date: 2022-05-09

Last Posted Date: 2024-10-26

Lead Sponsor: University of Miami

Target Recruit Count: 48

Registration Number: NCT05366816

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries

Phase 4

Withdrawn

Conditions: Chronic Shoulder Pain

Interventions: Drug: Lidocaine 1% Injectable Solution
Drug: Triamcinolone Injection
Procedure: Suprascapular Nerve Block

First Posted Date: 2022-05-06

Last Posted Date: 2023-12-06

Lead Sponsor: University of Miami

Registration Number: NCT05364099

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

Recruiting

Conditions: Smoldering Multiple Myeloma
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance

First Posted Date: 2022-05-05

Last Posted Date: 2025-03-17

Lead Sponsor: University of Miami

Target Recruit Count: 1000

Registration Number: NCT05361694

Locations: 🇺🇸
University of Miami Hospitals, Miami, Florida, United States

Addressing Psychosocial Comorbidities in HIV Treatment and Prevention 2b

Not Applicable

Conditions: Medication Adherence
Mental Health Issue

Interventions: Behavioral: CBT for Syndemics and Adherence Factors

First Posted Date: 2022-04-28

Last Posted Date: 2024-10-26

Lead Sponsor: University of Miami

Target Recruit Count: 75

Registration Number: NCT05352061

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

SpeakFree Heat and Moisture Exchanger (HME)

Not Applicable

Completed

Conditions: Laryngectomy
Laryngeal Cancer

Interventions: Device: SpeakFree HME Hands Free Valve
Other: Digital Occlusion
Device: Digital Depression HME

First Posted Date: 2022-04-27

Last Posted Date: 2025-02-03

Lead Sponsor: University of Miami

Target Recruit Count: 18

Registration Number: NCT05349487

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

Phase 2

Terminated

Conditions: Post Inflammatory Hyperpigmentation
Acne

Interventions: Other: Sunscreen
Drug: Liftactiv B3

First Posted Date: 2022-04-14

Last Posted Date: 2024-04-03

Lead Sponsor: University of Miami

Target Recruit Count: 13

Registration Number: NCT05327361

Locations: 🇺🇸
University of Miami Hospital, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy